The WHO criteria are perhaps most widely used, and define the accelerated phase by the presence of ≥1 of the following haematological/cytogenetic criteria or provisional criteria concerning response to tyrosine kinase inhibitor (TKI) therapy

Haematological/cytogenetic criteria
Persistent or increasing high white blood cell count (> 10 × 109/L), unresponsive to therapy
Persistent or increasing splenomegaly, unresponsive to therapy
Persistent thrombocytosis (> 1000 × 109/L), unresponsive to therapy
Persistent thrombocytopenia (< 100 × 109/L), unrelated to therapy
≥ 20% basophils in the peripheral blood
10―19% blasts in the peripheral blood and/or bone marrow
Additional clonal chromosomal abnormalities in Philadelphia (Ph) chromosome-positive (Ph+) cells at diagnosis, including so-called major route abnormalities (a second Ph chromosome, trisomy 8, isochromosome 17q, trisomy 19), complex karyotype, and abnormalities of 3q26.2
Any new clonal chromosomal abnormality in Ph+ cells that occurs during therapy
Provisional response-to-TKI criteria
Haematological resistance (or failure to achieve a complete haematological response d) to the first TKI
Any haematological, cytogenetic, or molecular indications of resistance to two sequential TKIs
Occurrence of two or more mutations in the BCR-ABL1 fusion gene during TKI therapyThe patient is considered to be in the accelerated phase if any of the above are present. The accelerated phase is significant because it signals that the disease is progressing and transformation to blast crisis is imminent. Drug treatment often becomes less effective in the advanced stages. Blast crisis
Blast crisis is the final phase in the evolution of CML, and behaves like an acute leukemia, with rapid progression and short survival.
Centrifugal abdominal lipodystrophy is a skin condition characterized by areas of subcutaneous fat loss that slowly enlarge. : 496–7

See also
Lipodystrophy
List of cutaneous conditions
Skin lesion


== References ==